Abraham Scaria
Company: Beacon Therapeutics
Job title: Chief Scientific Officer
Seminars:
Navigating Safety, Efficacy & Delivery for Ocular Gene Therapies to Treat Complement-Mediated Retinal Diseases 11:00 am
Exploring the critical need to prioritize complement targets with established clinical safety and efficacy profiles to mitigate the risks associated with sustained, irreversible therapeutic action Focussing on the complexities of achieving sufficient and consistent protein expression levels from gene therapy vectors to match the complement inhibition level seen with traditional biologics, particularly when targeting the…Read more
day: Conference Day Two
Panel Discussion: Discussing the Next-Generation of Novel Modalities to be Used for Enhanced Delivery & Broader Impact in CNS & Ophthalmic Indications 12:30 pm
Addressing the critical challenge of achieving sufficient complement inhibitor exposure in the CNS, a major reason for past failures with peripherally acting drugs Exploring novel delivery modalities like gene therapy, shuttle technologies that are in early development, to unlock the therapeutic potential of complement inhibition neurodegenerative diseases Highlighting the significant appeal and ongoing development of…Read more
day: Conference Day Two